Johnson & Johnson and Procter & Gamble were among the companies hit with a flurry of class action lawsuits in New York, Florida and Louisiana federal courts over their sale of over-the-counter decongestants, following a finding by an FDA advisory panel that phenylephrine, an ingredient in many allergy and cold medicines, is ineffective as a nasal decongestant.
And the attorneys who filed the lawsuits include Darren Kaplan, a partner at Kaplan Gore in New York, who represents a plaintiff, Sandra Yousefzadeh. Yousefzadeh’s filing says she purchased two packages of 24 tablets of Sudafed based on defendant Johnson & Johnson Consumer Inc.’s representation that Sudafed PE was an effective nasal decongestant.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]